natgillin/translations-raw huggingface dataset:
Baseline GLS Category at Rest 
Izhodiščna kategorija GLS v mirovanju
Human albumin, sodium chloride 
SEZNAM POMOŽNIH SNOVI Humani albumin, natrijev klorid
NUCEIVA should not be used during breast-feeding. 
Zdravilo NUCEIVA se ne sme uporabljati med dojenjem.
(listed in section 6); - if you have myasthenia gravis or Eaton Lambert syndrome (chronic diseases affecting the muscles); 
- če imate miastenijo gravis ali Lambert-Eatonov sindrom (kronični bolezni, ki prizadeneta mišice);
Application related undesirable effects that have been reported following administration of NUCEIVA are uncommon events individually, common when added together. 
Neželeni učinki, povezani z aplikacijo, o katerih so poročali po dajanju zdravila NUCEIVA, so posamezno občasni, če se seštejejo, pa pogosti.
Non-clinical data reveal no special hazard for humans based on conventional studies of acute and repeat dose toxicity. 
Neklinični podatki na osnovi običajnih študij akutne toksičnosti in toksičnosti pri ponavljajočih odmerkih ne kažejo posebnega tveganja za človeka.
Percentage 
Odstotek
Each vial contains 100 Units botulinum toxin type A After reconstitution each 0.1 mL of the solution contains 4 Units 
Ena viala vsebuje 100 enot botulinskega toksina tipa A. Po rekonstituciji 0,1 ml raztopine vsebuje 4 enote.
Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. 
Prekomerna živčno-mišična oslabelost se lahko stopnjuje, če se uporabi drug botulinski toksin pred prenehanjem učinkovanja predhodno uporabljenega botulinskega toksina.
Pre-existing neuromuscular disorders 
Predhodne živčno-mišične motnje
There is no information on whether NUCEIVA is excreted in human breast milk. 
Informacij, ali se zdravilo NUCEIVA izloča v materino mleko, ni na voljo.
NUCEIVA should only be administered by physicians with appropriate qualifications and expertise in the treatment of glabellar lines and the use of required equipment. 
Zdravilo NUCEIVA lahko dajo samo zdravniki, ki so ustrezno usposobljeni in imajo strokovno znanje o odpravljanju glabelarnih gub in uporabi potrebne opreme.
Injection of NUCEIVA is not recommended in patients with a history of dysphagia and aspiration. 
Injiciranje zdravila NUCEIVA ni priporočljivo pri bolnikih, ki so že imeli disfagijo in aspiracijo.
Caution should also be exercised when botulinum toxin type A is used for treatment of patients with amyotrophic lateral sclerosis or with peripheral neuromuscular disorders. 
Previdnost je potrebna tudi pri uporabi botulinskega toksina tipa A za zdravljenje bolnikov z amiotrofično lateralno sklerozo ali perifernimi živčno-mišičnimi motnjami.
The use of botulinum toxin is not recommended in association with aminoglycoside antibiotics, spectinomycin or other medicines that interfere with nerve impulses to the muscle. 
Uporaba botulinskega toksina ni priporočljiva v povezavi z aminoglikozidnimi antibiotiki, spektinomicinom ali drugimi zdravili, ki motijo prenos živčnih impulzov do mišic.
• Injection near the levator palpebrae superioris should be avoided, particularly in patients with larger brow depressor complexes. 
• preprečiti je treba injiciranje v bližino mišice dvigalke zgornje veke (m. levator palpebrae superioris), zlasti pri bolnikih z izrazitejšimi depresorji obrvi (m. depressor supercilii);
NUCEIVA is injected into your muscles (intramuscularly), directly into the affected area above and between the eyebrows. 
Zdravilo NUCEIVA se injicira v mišice (intramuskularno), neposredno na prizadeti predel nad in med obrvema.
Too frequent or excessive dosing may enhance the risk of antibody formation. 
S prepogostim ali prevelikim odmerjanjem se lahko poveča tveganje za nastanek protiteles, zaradi česar je lahko zdravljenje neuspešno.
Botulinum toxin type A (Clostridium botulinum neurotoxin) blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within the nerve endings, thereby leading to denervation of the muscle and a flaccid paralysis. 
Botulinski toksin tipa A (nevrotoksin bakterije Clostridium botulinum) blokira periferno sproščanje acetilholina iz holinergičnih presinaptičnih živčnih končičev s cepljenjem proteina SNAP-25, ki je nujen za uspešno kopičenje in sproščanje veziklov iz mešičkov živčnih končičev.
• If a vial is broken, carefully collect the pieces of glass and wipe up the product as stated above, avoiding cuts to the skin. 
• če se viala razbije, pazljivo zberite koščke stekla in zdravilo pobrišite, kot je navedeno zgoraj, pri čemer pazite, da se ne urežete;
In the event of treatment failure (no visible improvement of glabellar lines at maximum frown) one month after the first course of treatment, the following approaches may be considered: 
Če se v enem mesecu po prvem injiciranju pokaže, da zdravljenje ni bilo uspešno (brez vidnega izboljšanja glabelarnih gub pri najmočnejšem mrščenju), pridejo v poštev naslednji pristopi:
If the injector injures himself (cuts, pricks himself), proceed as above and take the appropriate medical steps. 
Če pri injiciranju zdravila poškodujete sebe (se urežete, zbodete), ukrepajte v skladu z zgoraj navedenim in sprejmite ustrezne medicinske ukrepe.
Dizziness, migraine, muscle tone disorder, speech disorder 
Omotica, migrena, motnje mišičnega tonusa, motnje govora
Do not use NUCEIVA after the expiry date which is stated on the vial and the carton after EXP. 
Zdravila NUCEIVA ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na viali in škatli poleg oznake „Uporabno do“.
After reconstitution each 0.1 mL of the solution contains 4 Units. 
Po rekonstituciji 0,1 ml raztopine vsebuje 4 enote.
Excessive doses may produce local or distant generalised and profound neuromuscular paralysis. 
Preveliki odmerki lahko povzročijo generalizirano in globoko nevromuskulatorno paralizo na mestu injiciranja ali daleč od njega.
However, another botulinum toxin type A has been shown to impair the fertility of male and female animals. 
Za drug botulinski toksin tipa A je bilo dokazano, da poslabša plodnost samcev in samic.
Headache, muscle imbalance resulting in elevated or asymmetrical eyebrows, eyelid drooping, injection site bruise 
Glavobol, neravnovesje mišic, kar ima za posledico dvignjene ali asimetrične obrvi, povešenje očesne veke, modrica na mestu injiciranja
NUCEIVA injections significantly reduced the severity of glabellar lines by 1 point or greater at maximum frown for up to 139 days, as measured by the investigator assessment of glabellar line severity at maximum frown. 
Z injiciranjem zdravila NUCEIVA se je za do 139 dni bistveno, za eno točko ali več, zmanjšala izraženost glabelarnih gub, vidnih pri najmočnejšem mrščenju, kar je bilo izmerjeno z raziskovalčevo oceno izraženosti glabelarnih gub pri najmočnejšem mrščenju.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 100 enot
Resulting dose (Units per 0.1 mL) 
Dobljeni odmerek (enot na 0,1 ml)
How to store NUCEIVA 6. 
Shranjevanje zdravila NUCEIVA 6.
NUCEIVA should only be injected by physicians with appropriate qualifications and expertise in the treatment of glabellar lines at maximum frown. 
Zdravilo NUCEIVA lahko injicirajo samo zdravniki, ki so ustrezno usposobljeni in imajo strokovno znanje o zdravljenju glabelarnih gub pri najmočnejšem mrščenju.
Uncommon (May affect up to 1 in 100 people) 
Pogosti (lahko se pojavijo pri največ 1 od
It is mandatory that NUCEIVA is used for one single patient treatment only during a single session. 
Zdravilo NUCEIVA je obvezno treba uporabiti za zdravljenje samo enega bolnika med eno terapijo.
540 patients with moderate to severe glabellar lines seen at maximum frown who felt their glabellar lines had an important psychological impact (on mood, anxiety/or depressive symptoms) have been included in the European/Canadian clinical study. 
V evropsko-kanadsko klinično študijo je bilo vključenih 540 bolnikov z zmerno do močno izraženimi glabelarnimi gubami, vidnimi pri najmočnejšem mrščenju, ki so menili, da imajo njihove glabelarne gube pomemben psihološki vpliv (na razpoloženje, simptome anksioznosti/depresivnosti).
Localised pain, inflammation, paraesthesia, hypoaesthesia, tenderness, swelling/oedema, erythema, localised infection, bleeding and/or bruising have been associated with the injection. 
Z injiciranjem so povezani lokalizirana bolečina, vnetje, mravljinčenje, hipestezija, občutljivost, otekanje/edem, eritem, lokalizirana okužba, krvavitev in/ali modrice .
Theoretically, the effect of botulinum toxin may be potentiated by aminoglycoside antibiotics, spectinomycin, or other medicinal products that interfere with neuromuscular transmission (e.g. neuromuscular blocking medicinal products). 
Učinek botulinskega toksina bi se teoretično lahko povečal z aminoglikozidnimi antibiotiki, spektinomicinom ali drugimi zdravili, ki motijo živčno-mišični prenos (npr. živčno-mišični blokatorji).
Pack size of one. 
Pakiranje z eno vialo.
NUCEIVA is used for the temporary improvement in the appearance of vertical lines between the eyebrows. 
Zdravilo NUCEIVA se uporablja za začasno izboljšanje videza navpičnih gub med obrvmi.
Each vial contains 100 Units botulinum toxin type A produced by Clostridium botulinum. 
Ena viala vsebuje 100 enot botulinskega toksina tipa A, ki ga proizvaja bakterija Clostridium botulinum.
Reconstituted NUCEIVA (100 Units/2.5 mL) is injected using a sterile 30 gauge needle. 
Rekonstituirano zdravilo NUCEIVA (100 enot/2,5 ml) se injicira s sterilno iglo velikosti 30 G.
Rarely occurring injection site events that have been reported include erythema, paraesthesia, pruritis, pain and tenderness. 
Redki primeri neželenih učinkov na mestu injiciranja, o katerih so poročali, vključujejo eritem, mravljinčenje, srbenje, bolečino in občutljivost.
There are limited phase 3 clinical data with NUCEIVA in patients older than 65 years. 
Pri bolnikih, starejših od 65 let, so za zdravilo NUCEIVA na voljo omejeni klinični podatki iz faze 3.
- The active substance is: 100 Units botulinum toxin type A. - The other ingredients are human albumin and sodium chloride. 
Kaj vsebuje zdravilo NUCEIVA - Učinkovina je: 100 enot botulinskega toksina tipa A. - Drugi sestavini sta humani albumin in natrijev klorid.
PHARMACEUTICAL PARTICULARS 6.1 List of excipients 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi Humani albumin
There is no relevant use of NUCEIVA in the paediatric population. 
Pediatrična populacija Zdravilo NUCEIVA ni namenjeno uporabi pri pediatrični populaciji.
In the event of overdose the patient should be medically monitored for symptoms of excessive muscle weakness or muscle paralysis. 
Ravnanje pri prevelikem odmerjanju V primeru prevelikega odmerjanja mora biti bolnik pod zdravniškim nadzorom, da se ugotovijo morebitni simptomi prekomerne mišične oslabelosti ali mišične paralize.
- the muscles to be injected are weak or wasted; - you have a bleeding disorder as injection may lead to bruising. 
- imate okužbo na predlaganem mestu injiciranja; - so mišice, v katere naj bi se injiciralo zdravilo, šibke ali oslabljene; - imate motnje strjevanja krvi, saj injiciranje lahko povzroči modrice.
If you have any difficulty in breathing, swallowing or speaking after receiving NUCEIVA contact your doctor immediately. 
Če imate po prejemu zdravila NUCEIVA težave pri dihanju, požiranju ali govoru, se takoj posvetujte z zdravnikom.
Application related adverse reactions 
Neželeni učinki, povezani z aplikacijo
No cases of systemic toxicity resulting from accidental injection of botulinum toxin type A have been observed. 
Primeri sistemske toksičnosti zaradi nenamernega injiciranja botulinskega toksina tipa A niso bili ugotovljeni.
- If the operator injures himself (cuts, pricks himself), proceed as above and take the appropriate medical steps according to the dose injected. 
- Če pri injiciranju zdravila poškodujete sebe (se urežete, zbodete), ukrepajte v skladu z zgoraj navedenim in sprejmite ustrezne medicinske ukrepe.
How to use NUCEIVA 
Kako uporabljati zdravilo NUCEIVA
The use of NUCEIVA is not recommended during pregnancy and in women able to have children who are not using contraception. 
Uporaba zdravila NUCEIVA ni priporočljiva med nosečnostjo in pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije.
Once reconstituted, NUCEIVA should only be used to treat a single patient, during a single session. 
Zdravilo NUCEIVA se po rekonstituciji lahko uporabi za zdravljenje samo enega bolnika med eno terapijo.
• Two injections should be administered in each corrugator muscle (inferior medial and superior medial aspect) and 1 injection in the procerus muscle for a total dose of 20 Units. 
• po dve injiciranji je treba dati v vsako mišico nagubalko obrvi (m. corrugator supercilii) (navzdol medialno in navzgor medialno) ter eno injiciranje v mišico m. procerus v skupnem odmerku 20 enot;
Muscle twitching, musculoskeletal pain, myalgia, neck pain 
Mišično trzanje, mišično-skeletna bolečina, mialgija, bolečine v vratu
Immediately after use, unused reconstituted NUCEIVA solution for injection in the vial and/or the syringe must be inactivated, prior to disposal, with 2 mL of dilute sodium hypochlorite solution at 0.5% or 1% available chlorine. 
Neuporabljeno rekonstituirano raztopino zdravila NUCEIVA za injiciranje v viali in/ali brizgi morate takoj po uporabi in preden jo zavržete inaktivirati z 2 mililitroma 0,5 % razredčene raztopine natrijevega hipoklorita ali 1 % prostim klorom.
Unit doses for NUCEIVA are not interchangeable with those used for other preparations of botulinum toxin. 
Odmerki enot zdravila NUCEIVA niso zamenljivi z odmerki, ki se uporabljajo pri drugih zdravilih z botulinskim toksinom.
NUCEIVA is not recommended during pregnancy and in women of childbearing potential not using contraception. 
Zdravila NUCEIVA ni priporočljivo uporabljati med nosečnostjo in pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije.
Skin and subcutaneous tissue disorders 
Bolezni kože in podkožja Srbenje
Glabellar Line Scale (GLS); 0=no lines, 1=mild, 2=moderate, 3=severe Two days after injection, 12.2% (6/49) of placebo, 57.0% (139/244) Botox treated patients and 54.2% (130/240) of NUCEIVA were considered by investigators as treatment responders (none or mild severity at maximum frown). 
Raziskovalci so menili, da se je dva dni po injiciranju na zdravljenje odzvalo 12,2 % (6/49) bolnikov, zdravljenih s placebom, 57,0 % (139/244) bolnikov, zdravljenih z zdravilom Botox, in 54,2 % (130/240) bolnikov, zdravljenih z zdravilom NUCEIVA (brez gub ali blaga izraženost pri najmočnejšem mrščenju).
• If splashed into the eyes, rinse eyes thoroughly with plenty of water or with an eye wash solution. 
• če zdravilo pride v oči, oči temeljito sperite z veliko vode ali raztopino za spiranje oči.
Dysaesthesia, head discomfort, hypoaesthesia, paraesthesia, sensory disturbance 
Disestezija, neprijeten občutek v glavi, hipestezija, mravljinčenje, senzorične motnje
Immediately after use, and prior to disposal, unused reconstituted NUCEIVA solution in the vial and/or the syringe must be inactivated, with 2 mL of dilute sodium hypochlorite solution at 0.5% or 1% (Javel solution) and should be disposed of in accordance with local requirements. 
Neuporabljeno rekonstituirano raztopino zdravila NUCEIVA v viali in/ali brizgi morate takoj po uporabi in preden jo zavržete inaktivirati z 2 mililitroma 0,5 % ali 1 % razredčene raztopine natrijevega hipoklorita (javelske raztopine), nato pa zavreči v skladu z lokalnimi predpisi.
Powder for solution for injection. 
FARMACEVTSKA OBLIKA Prašek za raztopino za injiciranje.
Amount of diluent added to 100 Unit vial (sodium chloride 9 mg/ml (0.9%) solution for injection) 2.5 mL 
Količina vehikla, dodanega 100 enotam viale (0,9 % (9 mg/ml) raztopina natrijevega klorida za injiciranje) 2,5 ml
These include application and injection site bruising, injection site pain and injection site swelling. 
Vključujejo modrice na mestu aplikacije in injiciranja, bolečino na mestu injiciranja in oteklino na mestu injiciranja.
Care should be taken to ensure that NUCEIVA is not injected into a blood vessel when it is injected in the vertical lines between the eyebrows seen at maximum frown (also known as glabellar lines) (see section 4.4). 
Paziti je treba, da se zdravilo NUCEIVA med injiciranjem v vertikalne gube med obrvmi, vidne pri najmočnejšem mrščenju (znane tudi kot glabelarne gube), ne injicira v krvno žilo (glejte poglavje 4.4).
100 Units 
100 oseb)
NUCEIVA injections also reduced the severity of glabellar lines at rest, an exploratory endpoint. 
Z injiciranjem zdravila NUCEIVA se zmanjša tudi izraženost glabelarnih gub v mirovanju, eksplorativni opazovani dogodek.
Responders for the Primary Efficacy Endpoint 
Bolniki, ki so se odzvali, kar zadeva primarni opazovani dogodek učinkovitosti
Adverse reactions possibly related to the spread of toxin distant from the site of administration have been reported very rarely with botulinum toxin (e.g. muscle weakness, breathing difficulties, dysphagia or constipation) (see section 4.4). 
Zelo redko so poročali o neželenih učinkih, ki so morebitno povezani s širjenjem botulinskega toksina daleč od mesta aplikacije (npr. mišična oslabelost, težave z dihanjem, disfagija ali zaprtost) (glejte poglavje 4.4).
Muscle atrophy is expected after repeated botulinum treatment secondary to the flaccid paralysis of the treated muscles. 
Po ponovljenem zdravljenju z botulinom se poleg flakcidne paralize zdravljenih mišic pričakuje atrofija mišic.
- If splashed into the eyes, rinse eyes thoroughly with plenty of water or with an eye wash solution. 
- če zdravilo pride v oči, oči temeljito sperite z veliko vode ali raztopino za spiranje oči.
Table 1 The NUCEIVA related adverse reactions are classified by System Organ Class and frequency defined as follows: Very common (≥ 1/10); common (≥ 1/100 to <1/10); uncommon (≥ 1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); very rare (<1/10,000). 
občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) in zelo redki (< 1/10.000).
NUCEIVA has a minor or moderate influence on the ability to drive and use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Zdravilo NUCEIVA ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja strojev.
Generalised disorders of muscle activity (e.g. myasthenia gravis or Eaton Lambert Syndrome) Infection or inflammation at the proposed injection sites. 
Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1; splošne motnje mišične dejavnosti (npr. miastenija gravis ali Lambert-Eatonov sindrom); okužba ali vnetje na predlaganih mestih injiciranja.
Resulting dose (Units per 0.1 mL) 4.0 U 
Dobljeni odmerek (enot na 0,1 ml) 4,0 enote
• Lateral corrugator injections should be placed at least 1 cm above the bony supraorbital ridge. 
• lateralni injiciranji v m. corrugator je treba opraviti vsaj 1 cm nad obrvnim lokom.
The anatomy and anatomical land marks of procerus corrugator supercilli muscles and the surrounding vasucular and nervous structures in the glabellar region must be understood prior to administration of NUCEIVA. 
Pred dajanjem zdravila NUCEIVA je treba razumeti anatomijo in anatomske orientacijske točke mišic procerus in corrugator supercilli ter okolišnje žilne in živčne strukture na glabelarnem predelu.
4.9 Overdose 
4.9 Preveliko odmerjanje Simptomi prevelikega odmerjanja
2.5 mL of sodium chloride 9 mg/ml (0.9%) solution for injection is drawn up into a syringe in order to obtain a reconstituted solution for injection at a concentration of 4 Units/0.1 mL. 
V brizgo potegnite 2,5 ml 0,9 % (9 mg/ml) raztopine natrijevega klorida za injiciranje, da dobite rekonstituirano raztopino za injiciranje v koncentraciji 4 enote/0,1 ml.
NUCEIVA is not recommended for use in patients over 65 years of age. 
Uporaba zdravila NUCEIVA pri bolnikih, starejših od 65 let, ni priporočljiva.
Admission to hospital should be considered in patients presenting with symptoms of botulinum toxin type A poisoning (generalised weakness, ptosis, diplopia, swallowing and speech disorders, or paresis of the respiratory muscles). 
Bolnike s simptomi zastrupitve z botulinskim toksinom tipa A (splošna oslabelost, ptoza, diplopija, motnje pri požiranju in govoru ali pareza dihalnih mišic) je treba sprejeti v bolnišnico.
NUCEIVA 100 Units powder for solution for injection 
IME ZDRAVILA NUCEIVA 100 enot prašek za raztopino za injiciranje
• If splashed on skin, wash with a solution of sodium hypochlorite and then rinse thoroughly with plenty of water. 
• če zdravilo poškropite po koži, površino umijte z raztopino natrijevega hipoklorita in nato temeljito sperite z veliko vode;
Botulinum toxin units are not interchangeable from one product to another. 
Enote botulinskega toksina med posameznimi zdravili niso zamenljive.
Inject the diluent slowly into the vial with a needle through the rubber stopper and gently rotate the vial avoiding bubble formation. 
Vehikel počasi z iglo injicirajte v vialo skozi gumijasti pokrovček, pri čemer vialo nekajkrat nežno krožno zavrtite, da preprečite nastajanje mehurčkov.
Side effects possibly related to the spread of botulinum toxin from the site of injection can occur very rarely (e.g. muscle weakness, difficulty in swallowing or food or liquid entering the airways). 
Opozorila in previdnostni ukrepi Neželeni učinki, ki so morebiti povezani s širjenjem botulinskega toksina z mesta injiciranja, se lahko pojavijo zelo redko (npr. mišična oslabelost, težave pri požiranju, vstop hrane ali tekočine v dihalne poti).
Bleeding disorders 
Hemoragične motnje
- If a vial is broken, carefully collect the pieces of glass and wipe up the product as stated above, 
- če se viala razbije, pazljivo zberite koščke stekla in zdravilo pobrišite, kot je navedeno zgoraj, pri čemer pazite, da se ne urežete;
- you see no significant improvement of your lines one month after your first course of treatment; - you suffer from certain diseases affecting your nervous system (such as amyotrophic lateral sclerosis or motor neuropathy); - you have inflammation at the proposed injection site(s); 
- imate določene bolezni, ki so prizadele vaš živčni sistem ( npr. amiotrofično lateralno sklerozo ali motorično nevropatijo);
- Contaminated surfaces must be cleaned with an absorbent material soaked in a solution of sodium hypochlorite (Javel solution) and then dried. 
- kontaminirane površine je treba očistiti z absorpcijskim materialom, namočenim v raztopini natrijevega hipoklorita (javelska raztopina), in nato posušiti;
NUCEIVA Vs. BOTOX 
NUCEIVA v primerjavi z zdravilom BOTOX
NUCEIVA has not been detected in the peripheral blood following intramuscular injection at the recommended dose. 
5.2 Farmakokinetične lastnosti Zdravilo NUCEIVA po njegovem intramuskularnem injiciranju v priporočenem odmerjanju v periferni krvi ni bilo zaznano.
Doses recommended are different from other botulinum toxin preparations. 
Priporočeni odmerki se razlikujejo od odmerkov drugih zdravil z botulinskim toksinom.
Pruritis 
Driska
Diplopia, dry eye, eyelid sensory disorder 
Diplopija, suhe oči, senzorične motnje očesne veke
Baseline GLS Score at Maximum Contraction 
Izhodiščni rezultati GLS pri najmočnejšem mrščenju
Denominators are based on the number of subjects with the specified baseline severity at rest who also had both baseline and Day 30 GLS scores at maximum contraction by investigator assessment 
Imenovalci temeljijo na številu oseb z določeno izhodiščno izraženostjo v mirovanju, pri katerih je bil na voljo tako izhodiščni rezultat GLS kot rezultat GLS na 30. dan pri najmočnejšem mrščenju na podlagi raziskovalčeve ocene.
• Contaminated surfaces must be cleaned with an absorbent material soaked in a solution of sodium hypochlorite (Javel solution) and then dried. 
• kontaminirane površine je treba očistiti z absorpcijskim materialom, namočenim v raztopini natrijevega hipoklorita (javelska raztopina), in nato posušiti;
Doses recommended in units are different from other botulinum toxin preparations. 
Priporočeni odmerki v enotah se razlikujejo od odmerkov drugih zdravil z botulinskim toksinom.